profit from every $100 of sales.
$0$100
BriaCell Therapeutics
We have no price for BriaCell Therapeutics since 6 March 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.00-0.00% today
-98.2% since Oct 9, 25
1-year low $0.001-year high $0.07
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
BriaCell Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BriaCell Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BriaCell Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.00
- 0.4×
- 0.0×
- –
- 0.6×
- -1,661,977.6%
- -367.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -123.6%
- 54.6%
- -221.7%
- -129.4%
- -123.6%
- –
Growth
- –
- –
- −14.6%
- –
- +8.9%
Financial health
- -0.8×
- 0.00
- 0.0%
- -504.1×
- 10.10
- 10.10
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 883
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Oct 31, 2023 | 0.36 | – | – |
| Apr 30, 2023 | -315.47 | – | – |
| Jan 31, 2023 | -765.68 | – | – |
| Oct 31, 2022 | -315.47 | – | – |
| Jul 31, 2022 | -1,242.25 | – | – |
| Oct 31, 2021 | 58.47 | – | – |
| Jul 31, 2021 | 147.85 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
64Pass
Benjamin Graham
81Pass
Philip Fisher
43No pass
Peter Lynch
62Pass
Joel Greenblatt
52No pass
Charlie Munger
47No pass
Terry Smith
44No pass
Questions about BriaCell Therapeutics
Is BriaCell Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BriaCell Therapeutics AI analysis
What does BriaCell Therapeutics do?
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is in Biotechnology.
Does BriaCell Therapeutics pay a dividend?
No. BriaCell Therapeutics does not pay a dividend at the moment.
Who are BriaCell Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BriaCell Therapeutics's.
Prices: daily closes to Mar 6, 2026. Fundamentals: company reports via invest-like data.